17 hrs ago
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
"Other recent notable achievements consist of advancing our internally discovered pipeline and lorcaserin life-cycle management programs, and establishing a marketing and supply agreement for BELVIQ in IMS Health estimates that approximately 110,000 prescriptions for BELVIQ were filled in the second quarter of 2014, representing growth of ... (more)
Thu Jul 31, 2014
Cramer's Lightning Round - 6 Biotech Picks
Arena Pharmaceuticals : "I'm not a fan of it. People got mad at me because of that, but the stock is down."
Wed Jul 30, 2014
Applied Clinical Trials
Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc...
The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin.
Mon Jul 28, 2014
Arena Conference Call Sets Stage For Near Term Equity Movement
Arena Pharmaceuticals will be hosting its quarterly conference call on Friday, August 1st, 2014 at 8:00 AM Eastern time.
Fri Jul 25, 2014
Arena Pharmaceuticals to Host Corporate Update and Financial Results...
Arena Pharmaceuticals, Inc. today announced that it will provide a corporate update and report second quarter 2014 financial results before the NASDAQ Global Select Market opens on Friday, August 1, 2014.
Mon Jul 21, 2014
San Diego Source
Arena subsidiary enters agreement with Israeli distributor for weight loss drug
Arena Pharmaceuticals Inc . announced on Monday that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement with Abic Marketing Limited, a Teva Pharmaceutical Industries subsidiary, for its weight loss and management product Belviq.
Fri Jul 18, 2014
Arena Stock Rises With Expected Jump In Belviq Sales
This week, we saw an anticipated pop in prescription numbers for the anti-obesity pill Belviq from Arena Pharmaceuticals .
Tue Jul 15, 2014
Applied Clinical Trials
Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office
8,778,950, entitled "Cannabinoid Receptor Modulators," by the United States Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 .
Thu Jul 10, 2014
Arena Pharmaceuticals Reports that Eisai Completes Planned Increase...
Arena Pharmaceuticals, Inc. today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ by 50% to approximately 600.
Mon Jul 07, 2014
Arena Prescription Sales OK - CEO Sales Are Not
Sales of Arena Pharmaceuticals prescription anti-obesity drug Belviq are in and are okay this week.
Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His Shares
Arena Pharmaceuticals shares plunged Monday on news that its chief executive Jack Lief sold nearly 40 percent of his holdings in the company.
Thu Jul 03, 2014
Arena Pharmaceuticals CEO Unloads $1,307,621 in Stock
Arena Pharmaceuticals CEO Jack Lief sold 223,525 shares of Arena Pharmaceuticals stock in a transaction that occurred on Tuesday, July 1st.